Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
F. Gelsomino
Observed name:
Francesco Gelsomino
Institution:
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Observed institution:
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
ORCID:
0000-0002-9204-1728
Observed ORCID:
0000-0002-9204-1728
OpenAlex ID:
A5037250969
1299P First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer
2024
·
A. Di Federico
, M.F. Chen
, et al.
·
Annals of Oncology
·
2
PDF
P2.06.92 Host-Derived Biomarkers of Inflammation and Body Composition Predict Immunotherapy Outcomes in Advanced NSCLC
2025
·
A. De Giglio
, M. Conte
, et al.
·
Journal of Thoracic Oncology
·
1
EP14.01-006 CeLEBrATE: Phase II trial of CarbopLatin, Etoposide, Bevacizumab and Atezolizumab in Patients with exTEnsive-Stage SCLC-GOIRC-01-2019
2022
·
E. Andrini
, G. Lamberti
, et al.
·
Journal of Thoracic Oncology
·
1
PDF
First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study
2016
·
M. Bersanelli
, F. Maines
, et al.
·
Annals of Oncology
·
1
302P Real-world attrition in neoadjuvant and perioperative immunotherapy-based treatment protocols in patients with locally-advanced non-small cell lung cancer: A multicenter national study
2026
·
F. Guerrera
, P. Bertoglio
, et al.
·
ESMO Open
108P Long-term real-world outcomes after first-line platinum– pemetrexed–pembrolizumab
2026
·
F. Perrone
, A. Leonetti
, et al.
·
ESMO Open
PDF
Central nervous system effectiveness of selpercatinib retreatment in heavily pretreated NSCLC patient with RET rearrangement: A case report
2026
·
Margherita Agostini
, Samuele Compagno
, et al.
·
Tumori Journal
P1.11.42 Dual Immune Checkpoint Blockade With CTLA-4 and PD-(L)1 Inhibitors in NSCLC: A Reconstructed Patient Data Meta-Analysis
2025
·
A. Di Federico
, S. Stumpo
, et al.
·
Journal of Thoracic Oncology
1343P Adding histology-driven chemotherapy (ChT) to overcome primary resistance to first-line immunotherapy (ICI) in patients (pts) with advanced non-small cell lung cancer (aNSCLC) with PD-L1 ≥50%
2024
·
A. De Giglio
, L. Zullo
, et al.
·
Annals of Oncology
Circulating immune-profile as predictor of outcome in NSCLC patients treated with nivolumab
2017
·
M. Tiseo
, M. Veneziani
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
10
Citation count:
5
H-index:
1
I10-index:
Year
Topic
Type